1. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.

2. Баранов А.А., Алексеева Е.И., editors. Ревматические болезни у детей. Москва: ПедиатрЪ 2016.

3. Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006; 54: 3971 - 8. doi: 10.1002/art.22207.

4. Volkmann ER. Systemic sclerosis. 2023; 401.

5. Williams JN, Speyer CB, Kreps DJ, et al. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus. 2019; 28: 1656 - 62. doi: 10.1177/0961203319886103.

6. Zulian F. Immunopathogenesis of Juvenile Systemic Sclerosis. Front Immunol. 2019; 10.

7. Foeldvari I, Torok KS, Anton J, et al. Proposed Response Parameters for Twelve Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings. Arthritis Care Res. 2023; 75: 2453 - 62. doi: 10.1002/acr.25171.

8. Foeldvari I, Klotsche J, Torok KS, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord. 2019; 4: 49 - 61. doi: 10.1177/2397198318790494.

9. Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006; 33: 1004 - 13.

10. Foeldvari I, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology. 2021; 60: 1651 - 8. doi: 10.1093/rheumatology/keaa584.

11. Zulian F. Scleroderma in Children. Pediatr Clin North Am. 2005; 52: 521 - 45. doi: 10.1016/j.pcl.2005.02.001.

12. Brennan P, Silman A, Black C, et al. Reliability of skin involvement measures in scleroderma. Rheumatology. 1992; 31: 457 - 60. doi: 10.1093/rheumatology/31.7.457.

13. Foeldvari I, Torok KS. Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points. Best Pract Res Clin Rheumatol. 2021; 35: 101688. doi: 10.1016/j.berh.2021.101688.

14. Li SC, O'Neil KM, Higgins GC. Morbidity and Disability in Juvenile Localized Scleroderma: The Case for Early Recognition and Systemic Immunosuppressive Treatment. J Pediatr. 2021; 234: 245 - 256. e2. doi: 10.1016/j.jpeds.2021.01.068.

15. Gyger G, Baron M. Systemic Sclerosis. Rheum Dis Clin N Am. 2015; 41: 459 - 73. doi: 10.1016/j.rdc.2015.04.007.

16. Kedia S, Chhaparia A, Garg P. Gastro-intestinal involvement in systemic sclerosis. Indian J Rheumatol. 2017; 12: 156. doi: 10.4103/0973-3698.219088.

17. Emmanuel A. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016; 13: 461 - 72. doi: 10.1038/nrgastro.2016.99.

18. Bagri NK, Raj D, Kaur J, et al. Juvenile systemic sclerosis: experience from a tertiary care center from India. Rheumatol Int. 2017; 37: 1687 - 91. doi: 10.1007/s00296-017-3793-3.

19. Wielosz E, Majdan M. Haematological abnormalities in systemic sclerosis. Rheumatology. 2020; 58: 162 - 6. doi: 10.5114/reum.2020.96655.

20. Тепаев Р.Ф. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология 2010; 7: 27 - 31.

21. Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child. 2017; 102: 187 - 93. doi: 10.1136/archdischild-2016-311053.

22. Ameri A, Anderson CM, Smith JH, et al. Thromboembolic Complications in a Pediatric Patient Population: Treatment with Direct Oral Anticoagulants. Monitoring of Treatment Efficiency with D-Dimer Levels and Safety Profile By Thromboelastogram. Blood. 2021; 138: 4270 - 4270. doi: 10.1182/blood-2021-146948.

23. Leak A, Patel KJ, Tuddenham EG, et al. Axillary vein thrombosis in adolescent onset systemic sclerosis. Ann Rheum Dis. 1990; 49: 557 - 9. doi: 10.1136/ard.49.7.557

24. Клинический протокол. Ювенильный системный склероз URL: https://diseases.medelement.com/disease/ювенильный-системный-склероз/14875?ysclid=mcn36s8koe931448244.

25. Klein A, Molad Y. Hematological Manifestations among Patients with Rheumatic Diseases. Acta Haematol. 2021; 144: 403 - 12. doi: 10.1159/000511759.

26. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e737S-e801S. doi: 10.1378/chest.11-2308.

27. Tarango C, Manco-Johnson MJ. Pediatric Thrombolysis: A Practical Approach. Front Pediatr. 2017; 5: 260. doi: 10.3389/fped.2017.00260.

28. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood. 2006; 107: 21 - 9. doi: 10.1182/blood-2004-11-4211.

29. M P, Salgado U A, Barriga G J, et al. Usefulness of the thromboelastogram in children: correlation with habitual coagulation tests. Rev Chil Pediatr. 2019; 90: 617 - 23. doi: 10.32641/rchped.v90i6.930.

30. Геморрагические и тромботические заболевания и синдромы у детей и подростков: патогенез, клиника, диагностика, терапия и профилактика: монография/Б.И. Кузник, В.Г. Стуров, Н.Ю. Левшин [и др.]. - 2-е изд., перераб. и доп. - Новосибирск: Наука, 2018. - 524 с.

31. Современные аспекты гемостазиологической диагностики у детей с тромбогеморрагическими осложнениями / А.А. Мартынов [и др.] // Практика педиатра. 2024. N 3. С. 53 - 60.

32. Тромбоэластография в клинической практике и диагностике: Методические рекомендации / Сыздыкова Б.С., Куанышев Е.Н. // Астана: АО "Национальный центр нейрохирургии", 2024. - 40 с.

33. Montagnana M, Lippi G, Volpe A, et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem. 2006; 39: 913 - 7. doi: 10.1016/j.clinbiochem.2006.03.016.

34. Breda, L., Nozzi, M., De Sanctis, S., & Chiarelli, F. (2010). Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update. Seminars in Arthritis and Rheumatism, 40(1), 53 - 72. doi: 10.1016/j.semarthrit.2008.12.

35. Jeong JE, Kim SH. Clinical characteristics of juvenile systemic sclerosis in Korea: 31-year single-center study. J Rheum Dis. 2024; 31: 25 - 32. doi: 10.4078/jrd.2023.0046.

36. Hachulla E, Agard C, Allanore Y, et al. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis. 2021; 16: 322. doi: 10.1186/s13023-021-01844-y.

37. Hanson V, Kornreich HK, Drexler E, et al. Some Immunologic Considerations in Focal Scleroderma and Progressive Systemic Sclerosis in Children. Pediatr Res. 1974; 8: 806 - 9. doi: 10.1203/00006450-197409000-00006.

38. Zulian F, Lanzoni G, Castaldi B, et al. Systemic sclerosis sine scleroderma in children. Rheumatology. 2022; 61: 2555 - 62. doi: 10.1093/rheumatology/keab738.

39. Russo RA, Katsicas MM. Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center. Pediatr Rheumatol. 2007; 5: 6. doi: 10.1186/1546-0096-5-6.

40. Jacquel L, Bechara R, Terzic J, et al. An updated overview of Juvenile systemic sclerosis in a French cohort. Pediatr Rheumatol. 2025; 23: 13. doi: 10.1186/s12969-024-01043-6.

41. Михельсон В.А., В.А. Сидоров, and С.М. Степаненко. "Анестезия и интенсивная терапия в педиатрии." М.: Дель рус (2007).

42. Голуб И.Е., Сорокина Л.В. Избранные вопросы по общей анестезиологии (методические рекомендации для клинических ординаторов, с правом переиздания). - 2005.

43. Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis. 2017; 20: 1313 - 25. doi: 10.1111/1756-185X.13129.

44. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015; 14: 503 - 9. doi: 10.1016/j.autrev.2015.01.011.

45. Овсянкина Е.С, Губкина М.Ф., Панова Л.В., Юхименко Н.В. Методы скрининга туберкулезной инфекции у детей и их роль в формировании групп риска и диагностике заболевания. Российский педиатрический журнал. 2017; 20 (2): 108 - 115. DOI: http://dx.doi.org/10.18821/1560-9561-2017-20 (2): 108 - 115.

46. Aksenova VA, Klevno NI, Kazakov AV, et al. Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study. Curr Pediatr. 2020; 19: 346 - 51. doi: 10.15690/vsp.v19i5.2210.

47. Clemente D, Cuadros EN, Lovillo MC, et al. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections. Eur J Pediatr. 2023; 183: 915 - 27. doi: 10.1007/s00431-023-05295-4.

48. Kwiatkowska B, Filipowicz-Sosnowska A. Reactive arthritis. Pol Arch Intern Med. 2009; 119: 60 - 6. doi: 10.20452/pamw.606.

49. Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice. Rheumatology. 2021; 60: 3969 - 76. doi: 10.1093/rheumatology/keab445.

50. Whyte LA, Al-Araji RA, McLoughlin LM. Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child - Educ Pract Ed. 2015; 100: 308 - 12. doi: 10.1136/archdischild-2014-307253.

51. J, Roggentin P. Enterale Yersiniosen. Klinische Bedeutung, Epidemiologie, Diagnostik und [Intestinal yersiniosis. Clinical importance, epidemiology, diagnosis, and prevention]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jul; 47(7): 685 - 91.

52. Shi T, Huang L, Tian J. Prevalence of Epstein-Barr Viral DNA among children at a single hospital in Suzhou, China. J Pediatr (Rio J). 2022; 98: 142 - 6. doi: 10.1016/j.jped.2021.05.006.

53. Soon GS, Laxer RM. Approach to recurrent fever in childhood. Can Fam Physician Med Fam Can. 2017; 63: 756 - 62.

54. Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2021; 11: 587380. doi: 10.3389/fimmu.2020.587380.

55. Engelmann I, Petzold DR, Kosinska A, et al. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol. 2008; 80: 467 - 77. doi: 10.1002/jmv.21095.

56. Liu Z, Zhang P, Tang S, et al. Urine real-time polymerase chain reaction detection for children virus pneumonia with acute human cytomegalovirus infection. BMC Infect Dis. 2014; 14: 245. doi: 10.1186/1471-2334-14-245.

57. A. Ross S, Novak Z, Pati S, et al. Overview of the Diagnosis of Cytomegalovirus Infection. Infect Disord - Drug Targets. 2011; 11: 466 - 74. doi: 10.2174/187152611797636703.

58. Slots J, Slots H. Bacterial and viral pathogens in saliva: disease relationship and infectious risk. Periodontol 2000. 2011; 55: 48 - 69. doi: 10.1111/j.1600-0757.2010.00361.x.

59. Strick LB, Wald A. Diagnostics for Herpes Simplex Virus: Is PCR the New Gold Standard? Mol Diagn Ther. 2006; 10: 17 - 28. doi: 10.1007/BF03256439.

60. Vince A, Dusek D. Imunosupresija i virusne infekcije u reumatskim bolestima [Immunosupression and viral infections in rheumatic diseases]. Reumatizam. 2007; 54(2): 58 - 62. Croatian. PMID: 18351141.

61. Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol. 2010; 8: 17. doi: 10.1186/1546-0096-8-17.

62. Looker KJ, Magaret AS, May MT, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLOS ONE. 2015; 10: e0140765. doi: 10.1371/journal.pone.0140765.

63. McQuillan G, Kruszon-Moran D, Flagg EW, et al. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14 - 49: United States, 2015 - 2016. NCHS Data Brief. 2018; 1 - 8.

64. Xu F, Lee FK, Morrow RA, et al. Seroprevalence of Herpes Simplex Virus Type 1 in Children in the United States. J Pediatr. 2007; 151: 374 - 7. doi: 10.1016/j.jpeds.2007.04.065.

65. Levin MJ, Weinberg A, Schmid DS. Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr. 2016; 4: 4.3.49. doi: 10.1128/microbiolspec.DMIH2-0017-2015.

66. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019; 4: 466 - 76. doi: 10.1016/S2468-1253(19)30042-1.

67. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020; 72: 671 - 722. doi: 10.1002/hep.31065.

68. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019; 4: 477 - 87. doi: 10.1016/S2468-1253(19)30046-9.

69. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370 - 98. doi: 10.1016/j.jhep.2017.03.021.

70. Key recommendations. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. World Health Organization 2010.

71. Okong'o LO, Webb K, Scott C. HIV-associated juvenile systemic sclerosis: A case report. Semin Arthritis Rheum. 2015; 44: 411 - 6. doi: 10.1016/j.semarthrit.2014.08.005.

72. Reust CE. Evaluation of primary immunodeficiency disease in children. Am Fam Physician. 2013; 87: 773 - 8.

73. Villard O, Cimon B, L'Ollivier C, et al. Serological diagnosis of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2016; 84: 22 - 33. doi: 10.1016/j.diagmicrobio.2015.09.009.

74. Cascio A., Colomba C. Childhood Mediterranean visceral leishmaniasis //Le Infezioni in Medicina. - 2003. - Т. 11. - N 1. - С. 5 - 10.

75. Limper M, de Kruif MD, Duits AJ, et al. The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect. 2010; 60: 409 - 16. doi: 10.1016/j.jinf.2010.03.016.

76. Kim YW, Kwon BS, Lim SY, et al. Diagnostic value of bronchoalveolar lavage and bronchial washing in sputum-scarce or smear-negative cases with suspected pulmonary tuberculosis: a randomized study. Clin Microbiol Infect. 2020; 26: 911 - 6. doi: 10.1016/j.cmi.2019.11.013.

77. Barahona-Correa JE, De La Hoz A, MJ, et al. Infections and systemic sclerosis: an emerging challenge. Rev Colomb Reumatol Engl Ed. 2020; 27: 62 - 84. doi: 10.1016/j.rcreue.2019.12.004.

78. Fioretto JR, Borin FDC, Bonatto RC, et al. Procalcitonin in children with sepsis and septic shock. J Pediatr (Rio J). 2004; 0. doi: 10.2223/JPED.1644.

79. Fioretto JR, Martin JG, Kurokawa CS, et al. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res. 2010; 59: 581 - 6. doi: 10.1007/s00011-010-0161-0.

80. Sakkas LI, Simopoulou T, Daoussis D, et al. Intestinal Involvement in Systemic Sclerosis: A Clinical Review. Dig Dis Sci. 2018; 63: 834 - 44. doi: 10.1007/s10620-018-4977-8.

81. Robinson JL, Lee BE, Kothapalli S, et al. Use of Throat Swab or Saliva Specimens for Detection of Respiratory Viruses in Children. Clin Infect Dis. 2008; 46: e61 - 4. doi: 10.1086/529386.

82. Chien Y-L, Huang F-L, Huang C-M, et al. Clinical approach to fever of unknown origin in children. J Microbiol Immunol Infect. 2017; 50: 893 - 8. doi: 10.1016/j.jmii.2015.08.007.

83. Ahmadinejad Z, Mansori S, Ziaee V, et al. Periodic Fever: a review on clinical, management and guideline for Iranian patients - part I. Iran J Pediatr 2014; 24: 1 - 13.

84. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020; 46: 10 - 67. doi: 10.1007/s00134-019-05878-6.

85. Howell MD, Davis AM. Management of Sepsis and Septic Shock. 2017; 2.

86. H, I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: Clinical and Laboratory Features and Prognostic Factors Influencing the Survival. Pediatr Hematol Oncol. 2005; 22: 679 - 88. doi: 10.1080/08880010500278749.

87. Misra R, Singh G, Aggarwal P, et al. Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia. Clin Rheumatol. 2007; 26: 1259 - 62. doi: 10.1007/s10067-006-0483-z.

88. Panigada S, Ravelli A, Silvestri M, et al. HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr Pulmonol. 2009; 44: 1226 - 34. doi: 10.1002/ppul.21141.

89. Takagi Y, Sasaki M, Eida S, et al. Comparison of salivary gland MRI and ultrasonography findings among patients with syndrome over a wide age range. Rheumatology. 2022; 61: 1986 - 96. doi: 10.1093/rheumatology/keab560.

90. Afzelius P, Nielsen M, Ewertsen C, et al. Imaging of the major salivary glands. Clin Physiol Funct Imaging. 2016; 36: 1 - 10. doi: 10.1111/cpf.12199.

91. Pavlov S, Damjanov N, P, et al. The Prognostic Value of Nailfold Capillary Changes for the Development of Connective Tissue Disease in Children and Adolescents with Primary Raynaud Phenomenon: A Follow up Study of 250 Patients. Pediatr Dermatol. 2006; 23: 437 - 42. doi: 10.1111/j.1525-1470.2006.00278.x.

92. Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, et al. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon. Rheumatol Int. 2012; 32: 3039 - 45. doi: 10.1007/s00296-011-2109-2.

93. Navallas M, Inarejos Clemente EJ, Iglesias E, et al. Connective Tissue Disorders in Childhood: Are They All the Same? RadioGraphics. 2019; 39: 229 - 50. doi: 10.1148/rg.2019180078.

94. Chapin R, Hant FN. Imaging of Scleroderma. Rheum Dis Clin N Am. 2013; 39: 515 - 46. doi: 10.1016/j.rdc.2013.02.017.

95. Boutry N, Hachulla , Zanetti-Musielak C, et al. Imaging features of musculoskeletal involvement in systemic sclerosis. Eur Radiol. 2007; 17: 1172 - 80. doi: 10.1007/s00330-006-0420-1.

96. Ambartsumyan L, Zheng HB, Iyer RS, et al. Relationship Between Esophageal Abnormalities on Fluoroscopic Esophagram and Pulmonary Function Testing in Juvenile Systemic Sclerosis. Arthritis Care Res. 2019; 71: 1444 - 9. doi: 10.1002/acr.23778.

97. JG, Mugii N, Inaoka PT, et al. Inflammatory myopathies overlapping with systemic sclerosis: a systematic review. Clin Rheumatol. 2022; 41: 1951 - 63. doi: 10.1007/s10067-022-06115-0.

98. Danaoui K, Nassih H, Oujennane K, et al. Juvenile Systemic Sclerosis: About 9 Cases. Open J Pediatr. 2024; 14: 320 - 6. doi: 10.4236/ojped.2024.142031.

99. Popescu NA, Manea D, Capitanescu G, et al. Respiratory Failure in a Rare Case of Juvenile Dermatomyositis - Systemic Scleroderma Overlap Syndrome. Maedica. 2020; 15: 394 - 400. doi: 10.26574/maedica.2020.15.3.394.

100. Houssini G. S. et al. Juvenile overlap syndrome: Considering scleromyositis //J Clin Images Med Case Rep. - 2024. - Т. 5. - N 4. - С. 2988.

101. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8: 1179 - 207. doi: 10.1016/j.crohns.2014.04.005.

102. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018; 67: 257 - 91. doi: 10.1097/MPG.0000000000002035.

103. Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev. 2018; 39: 542 - 9. doi: 10.1542/pir.2017-0234.

104. Tutar E, Kutluk G, Bayrak NA, et al. What is the diagnostic utility of endoscopic scoring systems in children? Turk J Gastroenterol. 2009; 24: 22 - 9. doi: 10.4318/tjg.2013.0700.

105. PT, Tolaymat OA, Bowman AW, et al. Gastrointestinal Manifestations of Rheumatological Diseases. Am J Gastroenterol. 2019; 114: 1441 - 54. doi: 10.14309/ajg.0000000000000260.

106. Kaniecki T, Abdi T, McMahan ZH. A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. Best Pract Res Clin Rheumatol. 2021; 35: 101666. doi: 10.1016/j.berh.2021.101666.

107. Gillett P, Hassall E. Pediatric gastrointestinal mucosal biopsy. Special considerations in children. Gastrointest Endosc Clin N Am. 2000; 10: 669 - 712, vi-vii.

108. Tringali A, Thomson M, Dumonceau J-M, et al. Pediatric gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Guideline Executive summary. Endoscopy. 2016; 49: 83 - 91. doi: 10.1055/s-0042-111002.

109. , Gabriela, et al. "Digestive hemorrhage in pediatric pathology." Romanian Journal of Pediatrics 61.3 (2012).

110. Foeldvari I. Juvenile Systemic Sclerosis. In: Sawhney S, Aggarwal A, eds. Pediatric Rheumatology. Singapore: Springer Singapore 2017: 403 - 11.

111. Cimaz, Rolando, and Thomas JA Lehman, eds. Pediatrics in systemic autoimmune diseases. Elsevier, 2016.

112. Zulian F. Scleroderma in children. Best Pract Res Clin Rheumatol. 2017; 31: 576 - 95. doi: 10.1016/j.berh.2018.02.004.

113. Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev. 2018; 39: 444 - 53. doi: 10.1542/pir.2017-0268.

114. AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology. 2018; 24: 73 - 85. doi: 10.1016/j.rppnen.2017.12.002.

115. Kowal-Bielecka O, R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68: 620 - 8. doi: 10.1136/ard.2008.096677.

116. Fonseca MB, Gomes FHR, Valera ET, et al. Signs and symptoms of rheumatic diseases as first manifestation of pediatric cancer: diagnosis and prognosis implications. Rev Bras Reumatol Engl Ed. 2017; 57: 330 - 7. doi: 10.1016/j.rbre.2017.01.007.

117. Alias A, Rodriguez EJ, Bateman HE, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis. 2012; 70: 109 - 14.

118. Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Idzior M, Sotniczuk M, et al. Ultrasonography, MRI and classic radiography of skin and MSK involvement in juvenile scleroderma. J Ultrason. 2020; 20: 311 - 7. doi: 10.15557/JoU.2020.0054.

119. Loctin A, Bailly F, Laroche D, et al. Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol. 2013; 32: 115 - 21. doi: 10.1007/s10067-012-2097-y.

120. Zucker EJ, Lee EY, Restrepo R, et al. Hip Disorders in Children. Am J Roentgenol. 2013; 201: W776 - 96. doi: 10.2214/AJR.13.10623.

121. Li Q. et al. Quantifying the contribution of 18F-FDG PET to the diagnostic assessment of pediatric patients with fever of unknown origin: a systematic review and meta-analysis //Pediatric Radiology. - 2022. - С. 1 - 12.

122. Colamussi P, Prandini N, Cittanti C, et al. Scintigraphy in rheumatic diseases. Best Pract Res Clin Rheumatol. 2004; 18: 909 - 26. doi: 10.1016/j.berh.2004.07.003.

123. JB. New imaging techniques in reumathology: MRI, scintigraphy and PET. Pol J Radiol. 2013; 78: 48 - 56. doi: 10.12659/PJR.889138.

124. Grebenyuk V. et al. Fever of unknown origin: case reports from routine clinical practice and a review //Klinicka Mikrobiologie a Infekcni Lekarstvi. - 2021. - Т. 27. - N 4. - С. 148 - 157.

125. D, J, Sipeki T. From "Sine Syndrome" to Syndrome. In: J, Herold M, M, eds. Sine Syndromes in Rheumatology. Vienna: Springer Vienna 2014: 31 - 6.

126. Lepri G, Catalano M, Bellando-Randone S, et al. Systemic Sclerosis Association with Malignancy. Clin Rev Allergy Immunol. 2022; 63: 398 - 416. doi: 10.1007/s12016-022-08930-4.

127. Аксенова В.А., Барышников Л.А., Клевно Н.И., et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы Современной Педиатрии 2011; 10: 16 - 22.

128. Borowiec A, Dabrowski R, Wozniak J, et al. Cardiovascular assessment of asymptomatic patients with juvenile-onset localized and systemic scleroderma: 10 years prospective observation. Scand J Rheumatol. 2012; 41: 33 - 8. doi: 10.3109/03009742.2011.609489.

129. Yuen, L. K., et al. "Case Report Two Cases of Juvenile Systemic Sclerosis and Literature Review." HK J Paediatr (New Series) 12.3 (2007): 221 - 226.

130. Ocallaghan C. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumatol. 2004; 18: 411 - 27. doi: 10.1016/j.berh.2004.03.002.

131. Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. Cham: Springer International Publishing 2019.

132. Gualtierotti R, Parisi M, Ingegnoli F. Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. Adv Ther. 2018; 35: 439 - 56. doi: 10.1007/s12325-018-0686-0.

133. K, Trieschmann U, Leister N. und Analgosedierung diagnostische Eingriffe bei Kindern. AINS - Intensivmed Notfallmedizin Schmerzther. 2023; 58: 409 - 20. doi: 10.1055/a-1925-7009.

134. Dumas G, Arabi YM, Bartz R, et al. Diagnosis and management of autoimmune diseases in the ICU. Intensive Care Med. 2024; 50: 17 - 35. doi: 10.1007/s00134-023-07266-7.

135. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002; 18: 729 - 48. doi: 10.1016/S0749-0704(02)00025-8.

136. Frye WS, Milojevic D. The Role of Psychology in Pediatric Rheumatic Diseases. Pediatr Clin North Am. 2022; 69: 965 - 74. doi: 10.1016/j.pcl.2022.05.009.

137. Foeldvari I, Torok KS, J, et al. Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022. Expert Rev Clin Immunol. 2024; 20: 387 - 404. doi: 10.1080/1744666X.2023.2298354.

138. Zulian F, Martini G. Childhood systemic sclerosis. Curr Opin Rheumatol. 2007; 19: 592 - 7. doi: 10.1097/BOR.0b013e3282f01625.

139. Van Den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013; 65: 2737 - 47. doi: 10.1002/art.38098.

140. R, HE, M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatol Int. 2020; 40: 771 - 6. doi: 10.1007/s00296-019-04498-z.

141. Lehrnbecher T, Groll AH. Infectious complications in the paediatric immunocompromised host: a narrative review. Clin Microbiol Infect. 2025; 31: 37 - 42. doi: 10.1016/j.cmi.2024.06.002.

142. Bula-Rudas FJ, Rathore MH, Maraqa NF. Salmonella Infections in Childhood. Adv Pediatr. 2015; 62: 29 - 58. doi: 10.1016/j.yapd.2015.04.005.

143. Daloglu H. Childhood Chlamydia Infections. In: Sarier M, ed. Infectious Diseases. IntechOpen 2023.

144. Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021; 22: 1579 - 92. doi: 10.1080/14656566.2021.1915989.

145. Eroglu Ertugrul NG, Yalcin E, Oguz B, et al. The value of flexible bronchoscopy in pulmonary infections of immunosuppressed children. Clin Respir J. 2020; 14: 78 - 84. doi: 10.1111/crj.13103.

146. Ers. Bronchoalveolar lavage in children. Eur Respir J. 2000; 15: 217 - 31. doi: 10.1183/09031936.00.15121700.

147. Daelemans, Siel & Peeters, Linde & Wachter, Elke & Malfroot, Anne. (2019). Challenges in Diagnosing Mycobacterial Infections in Children. 21. 194 - 199.

148. Xu D, Li S, Chen Z, et al. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr. 2011; 170: 851 - 8. doi: 10.1007/s00431-010-1360-y.

149. Copete AR, Vera C, Herrera M, et al. Mycoplasma pneumoniae in Children With and Without Community-acquired Pneumonia. What do PCR and Serology Say? Pediatr Infect Dis J. 2020; 39: e104 - 8. doi: 10.1097/INF.0000000000002636.

150. Restrepo-Gualteros SM, Gutierrez MJ, Villamil-Osorio M, et al. Challenges and Clinical Implications of the Diagnosis of Cytomegalovirus Lung Infection in Children. Curr Infect Dis Rep. 2019; 21: 24. doi: 10.1007/s11908-019-0681-x.

151. Gonski K, Cohn R, Widger J, et al. Utility of bronchoscopy in immunocompromised paediatric patients: Systematic review. Paediatr Respir Rev. 2020; 34: 24 - 34. doi: 10.1016/j.prrv.2020.02.003.

152. S, Bayram S. Investigation of Pneumocystis jirovecii Pneumonia and Colonization in Iatrogenically Immunosuppressed and Immunocompetent Patients. Mikrobiyol Bul. 2015; 49: 221 - 30. doi: 10.5578/mb.9344.

153. Lachant DJ, Croft DP, McGrane Minton H, et al. The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients. Respir Med. 2018; 145: 35 - 40. doi: 10.1016/j.rmed.2018.10.021.

154. Ramos JT, Romero CA, Belda S, et al. Clinical practice update of antifungal prophylaxis in immunocompromised children. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 2019; 32: 410 - 25.

155. Tragiannidis A, Kyriakidis I, I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-) inhibitors. Mycoses. 2017; 60: 222 - 9. doi: 10.1111/myc.12576.

156. Tan TC, Noviani M, Leung YY, et al. The microbiome and systemic sclerosis: A review of current evidence. Best Pract Res Clin Rheumatol. 2021; 35: 101687. doi: 10.1016/j.berh.2021.101687.

157. Barola S., Grossman O. K., Abdelhalim A. Urinary tract infections in children //StatPearls [Internet]. - StatPearls Publishing, 2024.

158. Lazzerini PE, Capecchi PL, Guideri F, et al. Comparison of Frequency of Complex Ventricular Arrhythmias in Patients With Positive Versus Negative Anti-Ro/SSA and Connective Tissue Disease. Am J Cardiol. 2007; 100: 1029 - 34. doi: 10.1016/j.amjcard.2007.04.048.

159. Zulian F, Balzarin M, Birolo C. Recent advances in the management of juvenile systemic sclerosis. Expert Rev Clin Immunol. 2017; 13: 361 - 9. doi: 10.1080/1744666X.2017.1243467.

160. Galindo-Zavala R, Bou-Torrent R, B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol. 2020; 18: 20. doi: 10.1186/s12969-020-0411-9.

161. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: ACR guideline for glucocorticoid-induced osteoporosis prevention and treatment. Arthritis Rheumatol. 2017; 69: 1521 - 37. doi: 10.1002/art.40137.

162. Athreya, Balu H., and Carol B. Lindsley. "Managing children with rheumatic diseases." Textbook of Pediatric Rheumatology E-Book (2010): 168.

163. Fc A. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update. 2017.

164. Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs.

165. Abad , Andreu JL, Caracuel Ruiz , et al. Position Paper From the Spanish Society of Rheumatology on Biosimilar Drugs. Reumatol Engl Ed. 2015; 11: 269 - 78. doi: 10.1016/j.reumae.2015.03.012.

166. Huizinga TWJ, Torii Y, Muniz R. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatol Ther. 2021; 8: 41 - 61. doi: 10.1007/s40744-020-00259-8.

167. Dills R, Anderson LA, Pierce CA. The role of nonsteroidal anti-inflammatory drugs in pediatric patients. Pharmacol Res. 2012; 65: 5 - 8. doi: 10.1016/j.phrs.2011.08.010.

168. Sherman JM, Sood SK. Current challenges in the diagnosis and management of fever. Curr Opin Pediatr. 2012; 24: 400 - 6. doi: 10.1097/MOP.0b013e32835333e3.

169. Баранов А.А., Алексеева Е.И., editors. Ревматические болезни у детей. Москва: ПедиатрЪ 2016.

170. Gupta P, Sachdev HP. Safety of oral use of nimesulide in children: systematic review of randomized controlled trials. Indian Pediatr. 2003 Jun; 40(6): 518 - 31. PMID: 12824661.

171. Guillaume-Czitrom S. Les anti-inflammatoires non dans les rhumatismes inflammatoires chroniques de l'enfant [Non-steroidal anti-inflammatory drugs in chronic inflammatory arthritis in children]. La Lettre du Rhumatologue N 379 - 380 - 2012.

172. Алексеева Е., Валиева С. Оценка эффективности, переносимости и безопасности нимесулида у детей с ювенильным артритом. Вопросы современной педиатрии. 2007; 6(6): 76 - 80.

173. Codina A, Walker KM, Pope JE, et al. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018; 70: 1820 - 8. doi: 10.1002/art.40560.

174. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54: 3962 - 70. doi: 10.1002/art.22204.

175. Zulian F, Tirelli F. Treatment in Juvenile Scleroderma. Curr Rheumatol Rep. 2020; 22: 45. doi: 10.1007/s11926-020-00910-x.

176. Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012; 67: 1151 - 6. doi: 10.1016/j.jaad.2012.03.036.

177. Hashkes PJ, Becker ML, Cabral DA, et al. Methotrexate: new uses for an old drug. J Pediatr. 2014; 164: 231 - 6. doi: 10.1016/j.jpeds.2013.10.029.

178. Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017; 69: 1451 - 60. doi: 10.1002/art.40114.

179. Lee K-A, Kim BY, Choi SJ, et al. A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study. Arch Rheumatol. 2020; 35: 366 - 75. doi: 10.46497/ArchRheumatol.2020.7771.

180. Ruaro B, Confalonieri M, Matucci-Cerinic M, et al. The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals. 2021; 14: 154. doi: 10.3390/ph14020154.

181. Weibel L. Diagnosis and management of morphoea in children: an overview. Clin Exp Dermatol. 2021; 46: 487 - 94. doi: 10.1111/ced.14562.

182. Souza AWSD, Dantas JG, Montandon ACDOES, et al. Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment. Adv Rheumatol. 2024; 64: 41. doi: 10.1186/s42358-024-00380-0.

183. Adrovic A, Yildiz M, Haslak F, et al. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study. Rheumatol Int. 2021; 41: 121 - 8. doi: 10.1007/s00296-020-04732-z.

184. Ogino MH, Tadi P. Cyclophosphamide. StatPearls. Treasure Island (FL): StatPearls Publishing 2024.

185. Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology. 2018; 57: 2106 - 13. doi: 10.1093/rheumatology/key213.

186. Zulian F, Dal Pozzolo R, Meneghel A, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology. 2020; 59: 3793 - 7. doi: 10.1093/rheumatology/keaa193.

187. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015; 74: 1188 - 94. doi: 10.1136/annrheumdis-2013-204522.

188. Sulieman SE, Metjian TA, Zaoutis TE, et al. Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. Curr Fungal Infect Rep. 2014; 8: 45 - 55. doi: 10.1007/s12281-014-0177-y.

189. Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review. Semin Arthritis Rheum. 2020; 50: 645 - 56. doi: 10.1016/j.semarthrit.2020.03.020.

190. Tang J, Zheng W, Yang B. P08 Successful treatment of paediatric morphoea with tofacitinib. Br J Dermatol. 2023; 188: ljad113.036. doi: 10.1093/bjd/ljad113.036.

191. Алексеева Е.И., Крехова Е.А., Криулин И.А., Криулина Т.Ю., Дворяковская Т.М., Исаева К.Б., Чистякова Е.Г., Чомахидзе А.М., Ломакина О.Л., Фетисова А.Н., Чибисова К.В., Цулукия И.Т., Шингарова М.Ш., Ботова М.С., Кондратьева Н.М., Кокина М.Ю., Румянцев М.А. Опыт применения ингибитора янус-киназ упадацитиниба у детей с ревматическими болезнями. Вопросы практической педиатрии. 2024; 19(2): 59 - 79. DOI: 10.20953/1817-7646-2024-2-59-79.

192. Walker KM, Pope J. Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A Consensus of Systemic Sclerosis Experts. Semin Arthritis Rheum. 2012; 42: 42 - 55. doi: 10.1016/j.semarthrit.2012.01.003.

193. Shouval DS, Mukamel M, Zulian F, et al. Iloprost treatment for refractory Raynaud's phenomenon in two infants. Clin Exp Rheumatol. 2008; 26: S 105 - 107.

194. Bartolone S, Trifiletti A, De Nuzzo G, et al. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon. Minerva Cardioangiol. 1999; 47: 137 - 43.

195. Langevitz P, Buskila D, Lee P, et al. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions. J Rheumatol. 1989; 16: 1433 - 5.

196. Juche A, Siegert E, Mueller-Ladner U, et al. der vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen bei systemischer Sklerose in Deutschland. Z Rheumatol. 2020; 79: 1057 - 66. doi: 10.1007/s00393-019-00743-9.

197. Гусева Н. Вазапростан в комплексном лечении системной склеродермии и синдрома Рейно / Н. Гусева // Врач. - 2006. - N 5. - С. 46 - 50.

198. Linnemann B, Erbe M. Raynaud's phenomenon and digital ischaemia - pharmacologic approach and alternative treatment options. Vasa. 2016; 45: 201 - 12. doi: 10.1024/0301-1526/a000526.

199. Distler JHW. und . Z Rheumatol. 2008; 67: 211 - 9. doi: 10.1007/s00393-008-0282-9.

200. Adrovic A. Juvenile Scleroderma: A Referral Center Experience. Arch Rheumatol. 2018; 33: 344 - 51. doi: 10.5606/ArchRheumatol.2018.6578.

201. Milan MJDC, Dans LF, Torres-Ticzon VMF. Acute limb ischemia in an adolescent with COVID-19 and systemic scleroderma: a case report. BMC Pediatr. 2022; 22: 737. doi: 10.1186/s12887-022-03761-w.

202. Davuluri S, Lood C, Chung L. Calcinosis in systemic sclerosis. Curr Opin Rheumatol. 2022; 34: 319 - 27. doi: 10.1097/BOR.0000000000000896.

203. Aleksandrov AA, Kisliak OA, Leontyeva IV. Clinical guidelines on arterial hypertension diagnosis, treatment and prevention in children and adolescents. Syst Hypertens. 2020; 17: 7 - 35. doi: 10.26442/2075082X.2020.2.200126.

204. Garcia De La Pena-Lefebvre P, Rodriguez Rubio S, Valero Exposito M, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology. 2007; 47: 464 - 6. doi: 10.1093/rheumatology/ken001.

205. Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019; 15: 383 - 9. doi: 10.1080/1744666X.2019.1562905.

206. Кокина М.Ю., Фомина Д.С., Лебедкина М.C., Мутовина З.Ю., Жолобова Е.С., Курбанова С.Х., Наргизян А.К., Фетисова А.Н., Анджель А.Е., Дворяковская Т.М., Шилькрот И.Ю., Алексеева Е.И. Эффективность и безопасность применения двухкомпонентного препарата моноклональных антител к SARS-CoV-2 (тиксагевимаб + цилгавимаб) для доконтактной профилактики новой коронавирусной инфекции у иммунокомпрометированных пациентов детского возраста с ревматическими заболеваниями. Предварительные результаты первого в Российской Федерации проспективного наблюдательного когортного исследования. Вопросы практической педиатрии. 2023; 18(1): 16 - 26.

207. Hsieh L-F, Mao H-F, Lu C-C, et al. Rheumatologic Rehabilitation. Braddom's Physical Medicine and Rehabilitation. Elsevier 2021: 606 - 626. e1.

208. Stucki G, Kroeling P. Physical therapy and rehabilitation in the management of rheumatic disorders. Best Pract Res Clin Rheumatol. 2000; 14: 751 - 71. doi: 10.1053/berh.2000.0111.

209. Luttosch F, Baerwald C. Rehabilitation in der Rheumatologie. Internist. 2010; 51: 1239 - 45. doi: 10.1007/s00108-010-2626-1.

210. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011; 70: 1704 - 12. doi: 10.1136/ard.2011.150193.

211. Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Чистякова Е., Слепцова Т., Митенко Е. Эффективность и безопасность отечественного рекомбинантного человеческого гранулоцитарного колониестимулирующего фактора при нейтропениях, развивающихся на фоне анти-в клеточной и иммуносупрессивной терапии у больных ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2010; 9(4): 94 - 100.

212. Yilmaz D., Ritchey A. K. Severe neutropenia in children: a single institutional experience //Journal of Pediatric Hematology/Oncology. - 2007. - Т. 29. - N 8. - С. 513 - 518.

213. Segel, G. B., & Halterman, J. S. (2008). Neutropenia in pediatric practice. Pediatrics in review, 29(1), 12.

214. Novelli, V., & Holzel, H. (1999). Safety and tolerability of fluconazole in children. Antimicrobial agents and chemotherapy, 43(8), 1955 - 1960.

215. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin Replacement Therapy in Children. Immunol Allergy Clin North Am. 2008; 28: 833 - 49. doi: 10.1016/j.iac.2008.07.001.

216. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann. 2017; 46. doi: 10.3928/19382359-20161214-01.

217. Scientific Centre of Children's Health, Moscow, Russian Federation, Alexeeva EI, Denisova RV, et al. Intravenous Immunoglobulin in Pediatric Rheumatology Practice. Curr Pediatr Vopr Sovrem Pediatr. 2015; 14: 219 - 23. doi: 10.15690/vsp.v14i2.1290.

218. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology. 2015; 54: 383 - 91. doi: 10.1093/rheumatology/keu429.

219. Prasad AN, Chaudhary S. Intravenous immunoglobulin in pediatrics: A review. Med J Armed Forces India. 2014; 70: 277 - 80. doi: 10.1016/j.mjafi.2013.05.011.

220. Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, Inc 2020.

221. Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus: Table 1. Rheumatology. 2016; kew340. doi: 10.1093/rheumatology/kew340.

222. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care. 2012; 16: R52. doi: 10.1186/cc11256.

223. El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, et al. Intravenous Polyclonal Immunoglobulin Administration to Sepsis Syndrome Patients: A Prospective Study in a Pediatric Intensive Care Unit. J Trop Pediatr. 2005; 51: 271 - 8. doi: 10.1093/tropej/fmi011.

224. Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019; 10: 1990. doi: 10.3389/fimmu.2019.01990.

225. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011; 30: 1163 - 72. doi: 10.1007/s10067-011-1720-7.

226. Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous Acyclovir and Renal Dysfunction in Children: A Matched Case Control Study. J Pediatr. 2015; 166: 1462 - 1468. e4. doi: 10.1016/j.jpeds.2015.01.023.

227. Kimberlin DW. Acyclovir Dosing in the Neonatal Period and Beyond. J Pediatr Infect Dis Soc. 2013; 2: 179 - 82. doi: 10.1093/jpids/pis138.

228. Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol. 2002; 4: 231 - 7. doi: 10.1007/s11940-002-0040-2.

229. Antiviral Drugs in Children and Adolescents. Pediatr Infect Dis. 2020; 1: 123 - 8. doi: 10.5005/jp-journals-10081-1221.

230. Zhang S, Zhu Y, Jin Y, et al. Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein-Barr Virus-Associated Infectious Mononucleosis. Evid Based Complement Alternat Med. 2021; 2021: 1 - 6. doi: 10.1155/2021/8996934.

231. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013; 162: 376 - 82. doi: 10.1111/bjh.12386.

232. Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014; 13: 546 - 9. doi: 10.1016/j.autrev.2014.01.005.

233. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017; 64: 991 - 1003. doi: 10.1097/MPG.0000000000001594.

234. Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter. 2021; 26: e12825. doi: 10.1111/hel.12825.

235. Бельмер С.В., Корниенко Е.А., Волынец Г.В., Гурова М.М., Звягин А.А., Камалова А.А., Луппова Н.Е., Нижевич А.А., Новикова В.П., Печкуров Д.В., Приворотский В.Ф., Сатаев В.У., Тяжева А.А., Файзуллина Р.А., Хавкин А.И. Диагностика и лечение хеликобактерной инфекции у детей. Экспериментальная и клиническая гастроэнтерология. 2021; (9): 119 - 127. https://doi.org/10.31146/1682-8658-ecg-193-9-119-127.

236. Рубрикатор клинических рекомендаций. Язвенная болезнь желудка и/или двенадцатиперстной кишки. URL: https://cr.minzdrav.gov.ru/view-cr/388_3.

237. What's New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 Apr 2020).

238. Pneumonia in Immunocompromised Patients: Overview, Causes of Pneumonia, HIV/AIDS. Published Online First: 26 June 2021.https://emedicine.medscape.com/article/807846-overview#a11.. (accessed 10 Aug 2021).

239. Douglas AP, Smibert OliviaC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021; 51: 143 - 76. doi: 10.1111/imj.15591.

240. What's New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 Apr 2020).

241. Kutilek S, Plasilova I, Langer J. Ibandronate in the treatment of pediatric osteoporosis. Bone Abstr. Published Online First: 9 June 2015. doi: 10.1530/boneabs.4.P80.

242. Лисицин А., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т. Опыт применения ибандроновой кислоты у больных с тяжелым течением ревматических болезней и системным остеопорозом. Вопросы современной педиатрии. 2010; 9(1): 116 - 121.

243. Bachrach LK, Ward LM. Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. J Clin Endocrinol Metab. 2009; 94: 400 - 9. doi: 10.1210/jc.2008-1531.

244. Денисова Р., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т., Исаева К., Морев С., Кузнецова Г. Эффективность и безопасность ибандроновой кислоты для внутривенного введения при тяжелом системном остеопорозе у больных ювенильным артритом. Вопросы современной педиатрии. 2011; 10(6): 83 - 88.

245. Trapani S, Grisolia F, Simonini G, et al. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum. 2000; 29: 348 - 59. doi: 10.1053/sarh.2000.5752.

246. Hernandez J, Polo R, Alvarez J, et al. [A "lupus-like" syndrome as the form of presentation of pulmonary adenocarcinoma]. An Med Interna Madr Spain 1984. 2000; 17: 558 - 9.

247. Calixto O-J, Franco J-S, Anaya J-M. Lupus mimickers. Autoimmun Rev. 2014; 13: 865 - 72. doi: 10.1016/j.autrev.2014.05.002.

248. Ladouceur A, Tessier-Cloutier B, Clarke AE, et al. Cancer and Systemic Lupus Erythematosus. Rheum Dis Clin N Am. 2020; 46: 533 - 50. doi: 10.1016/j.rdc.2020.05.005.